Search Results - xinshu+xiao

17 Results Sort By:
Non-Coding Functional Variants as Cancer Biomarkers (UCLA Case No. 2023-289)
UCLA researchers from the Department of Integrative Biology and Physiology have developed a novel method to identify rare 3’ UTR variants that regulate mRNA abundance, with potential applications in predicting cancer patient survival. BACKGROUND: Non-coding genetic variants play a significant role in diseases such as cancer yet identifying those...
Published: 9/17/2025   |   Inventor(s): Xinshu Xiao
Keywords(s):  
Category(s): Life Science Research Tools > Screening Libraries, Therapeutics > Oncology
Double-Stranded RNA Expression Signatures to Predict Response to Cancer Therapy (UCLA Case No. 2022-218)
UCLA researchers from the Department of Integrative Biology and Physiology have developed a novel method to profile RNA editing in single cells from lung cancer biopsies as a method to predict patient survival. BACKGROUND: RNA editing occurs naturally in the human transcriptome and has been shown to influence cancer cell behavior and the anti-tumor...
Published: 9/17/2025   |   Inventor(s): Xinshu Xiao, Ting Fu
Keywords(s):  
Category(s): Diagnostic Markers > Cancer, Therapeutics > Oncology, Therapeutics > Immunology And Immunotherapy
Discovery of potent and selective D3 antagonist with alleviated hERG liability and optimized pharmacokinetic properties
One of the most challenging hurdles in creating safe and effective new medicines for many diseases is finding drugs that are effective without causing off-target cardiac issues, such as cardiac arrythmias. In collaboration with NIDA, scientists at NCATS have developed a series of novel and highly specific dopamine D3 receptor agonists and antagonists...
Published: 6/13/2025   |   Inventor(s): Khalida Shamim, Wenwei Huang, Wei Zheng, Catherine Chen, Xiuli Huang, Xin Hu, Xin Xu, Pranav Shah, Elias Padilha, Philip Sanderson, Amy Newman
Keywords(s):  
Category(s): Application > Therapeutics, Collaboration Sought > Licensing, Collaboration Sought > Materials Available, TherapeuticArea > Neurology, TherapeuticArea > Psychiatry/Mental Health
CD206 Small Molecule Modulators, Their Use and Methods for Preparation
Abstract: Pancreatic ductal adenocarcinoma (PDA) accounts for more than 90% of pancreatic cancer cases, and it is one of the most aggressive malignancies with a 5-year survival rate of 6%. The high mortality rate caused by PDA is primarily from the lack of early diagnosis – it is often asymptomatic in early stages – and a poor response to conventional...
Published: 4/22/2025   |   Inventor(s): Udo Rudloff, Juan Marugan, Xin Hu, Raul Calvo, Noel Southall, Bolormaa Baljinnyam
Keywords(s): CD206, M1 Macrophage, M2 Macrophage, Pancreatic Cancer, Pancreatic Ductal Adenocarcinoma, PDA, Rudloff, TAM, Tumor-Associated Macrophages
Category(s): Collaboration Sought > Licensing, Application > Therapeutics, TherapeuticArea > Oncology, Collaboration Sought > Collaboration
The Use of Emetine for the Treatment of SARS-CoV-2 Infection
This technology includes the clinical use of the small compound emetine for the treatment of SARS-CoV-2. Previous work has shown that emetine has antiviral properties against some DNA and RNA viruses. It is thought that the mechanism may involve blocking protein synthesis. Work has shown that emetine has potential antiviral activity in multiple tissues...
Published: 10/28/2024   |   Inventor(s): Mark Henderson, Juan Marugan, Andreas Dulcey Garcia, Xin Hu, Marc Ferrer-Alegre, Noel Southall
Keywords(s): Emetine, Infection, SARS-CoV-2, treatment, VLXXXX, WIXXXX, WKXXXX
Category(s): TherapeuticArea > Infectious Disease, Application > Therapeutics, Application > Research Materials
Creation of a High-density Screening Format and the Identification of Small Molecule Inhibitors of the SIX/EYA Interaction for the Treatment of Cancers
The technology includes the creation of a high-throughput assay and the identification and use of small molecules that inhibit the SIX/EYA interaction as a treatment for cancer. The Eya proteins are phosphatases that form a complex and are activated by the Six family of homeobox transcription factors. The interaction of Eya and Six mediates breast cancer...
Published: 10/28/2024   |   Inventor(s): Marc Ferrer-Alegre, Xin Hu, Juan Marugan, Lesley Mathews, Heide Ford, Melanie Blevins, Rebecca Mull, Rui Zhao
Keywords(s): cancers, Identification, Identifying, Inhibitors, INTERACTION, Listed LPM Vathyam as of 4/15/2015, Method, MOLECULE, Post LPM Assignment Set 20150420, Pre LPM working set 20150418, SIX/EYA, Small, treatment, VCXXXX, WIXXXX, WKXXXX, XEXXXX
Category(s): Application > Research Materials, Application > Therapeutics, TherapeuticArea > Oncology
Identification and Use of a Novel Functionally Selective GHSR1a Ghrelin Receptor Inhibitor, including NCGC00538279, for the Treatment of Food and Chemical Addiction
This technology includes a chemical series, including the NCGC00538279 compound, that selectively activates the GHSR1a G-protein pathway for calcium mobilization while only partially activating the beta-arrestin-2 translocation pathway. The resulting chemical series may be therapeutically valuable for addictive disorders. Activation of the GHSR1a G-protein...
Published: 8/19/2025   |   Inventor(s): Noel Southall, Marc Ferrer-Alegre, Daniel Jansen, Mark Henderson, Xin Hu, David Kim, Juan Marugan
Keywords(s): ADDICTION, Chemical, FOOD, Funtionally, Ghrelin, LIGAND, NCG00538279, Novel, RECEPTOR, SELECTIVE, treatment, VEXXXX, VGXXXX, WIXXXX, WKXXXX, XEXXXX
Category(s): TherapeuticArea > Neurology, Application > Therapeutics, TherapeuticArea > Endocrinology, Application > Research Materials
Heterocyclic Compounds for the Treatment of Hepatitis C Virus
The vast majority of people infected with Hepatitis C Virus (HCV) will have chronic infection. Over decades, this can lead to liver disease and liver cancer. In fact, HCV infection is the leading cause of liver transplants in the U.S. Several new drugs have recently come into the market that have changed the HCV treatment paradigm. However, the...
Published: 10/28/2024   |   Inventor(s): Zongyi Hu, Juan Marugan, Noel Southall, Xin Hu, Jingbo Xiao, Shanshan (Melissa) He, Marc Ferrer-Alegre, Wei Zheng, Kevin Frankowski, Frank Schoenen, Kelin Li, Tsanyang (Jake) Liang
Keywords(s): C, Class, compounds, DB4BXX, Development, Hepatitis, Novel, treatment, VLXXXX, WKXXXX, YAXXXX, YBXXXX
Category(s): Collaboration Sought > Licensing, Application > Therapeutics, TherapeuticArea > Infectious Disease
Fine-Tune Cellulose Crystals in Biocomposites
Morphology change from crystalline (I. Pure Cellulose) to amorphous (III. coagulated in water) or semi-crystalline (IV. coagulated in H2O2) Invention Summary: Natural materials such as cellulose or silk can be used in a multitude of applications such as electrolyte batteries, filters, drug delivery systems and scaffolds for tissue engineering....
Published: 8/12/2025   |   Inventor(s): David Salas-De La Cruz, Xiao Hu, Stacy Love, David Verrill
Keywords(s): Biomaterials, Chemical and petrochemical industry, Membranes, Nanotechnology
Category(s): Technology Classifications > Physical Sciences & Engineering, Technology Classifications > Polymers/Composites/Materials
2018-910 Prediction of Cardiac Arrest Using Continuous Electrocardiogram
SUMMARYUCLA researchers in the Geffen School of Medicine have developed a method to accurately and timely predict cardiac arrest in hospital patients based on a patient’s own data. This method allows for fewer and more relevant alarms that improve the chance of survival from a cardiac arrest episode.BACKGROUNDIn the United States, over 200,000...
Published: 8/25/2025   |   Inventor(s): Duc Do, Noel Boyle, Alan Kuo, Xiao Hu
Keywords(s):  
Category(s): Software & Algorithms > Digital Health, Medical Devices > Monitoring And Recording Systems, Therapeutics > Cardiovascular
1 2